Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 465 across all filing types
Latest filing 2023-04-24 Capital/Financing Update
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by IDEAYA Biosciences, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is clearly related to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to clear identification of the document as a prospectus supplement for a stock offering.
2023-04-24 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes preliminary financial estimates for the quarter ended March 31, 2023, and updates on the company's 'at-the-market' stock offering program. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), nor is it a full Annual Report (10-K). It is not a certification or officer attestation, so it is not Regulatory Filings (RNS). The document primarily provides an update on financial condition and capital raising activities, which aligns with the Capital/Financing Update (CAP) category. The length is about 5000 characters, and the document is the report itself, not just an announcement of a report. Therefore, the best classification is Capital/Financing Update (CAP).
2023-04-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on clinical updates and interim results from ongoing clinical trials, including Phase 2 and Phase 2/3 trials, as well as FDA guidance and forward-looking statements. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, audit report, or management discussion. It is a regulatory filing reporting significant clinical trial updates and other material events. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed clinical data support that this is a substantive regulatory announcement rather than a brief report publication announcement or a simple notice.
2023-04-24 English
Director's Dealing 2023
Director's Dealing
2023-04-14 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-14 English
Director's Dealing 2023
Director's Dealing
2023-04-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.